Coverage
-
August 09, 2019
A New Jersey federal judge Friday rejected Sandoz Inc.'s attempt to invalidate two patents covering Amgen subsidiary Immunex Corp.'s blockbuster immunosuppressant Enbrel, stalling Sandoz's aim to launch a biosimilar version of the drug.
1 other articles on this case.
View all »